Nordea Investment Management AB Has $5.18 Million Holdings in Pediatrix Medical Group, Inc. $MD

Nordea Investment Management AB decreased its holdings in Pediatrix Medical Group, Inc. (NYSE:MD) by 12.7% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 239,853 shares of the company’s stock after selling 34,927 shares during the quarter. Nordea Investment Management AB’s holdings in Pediatrix Medical Group were worth $5,183,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of MD. JPMorgan Chase & Co. raised its position in Pediatrix Medical Group by 20.5% during the 3rd quarter. JPMorgan Chase & Co. now owns 827,075 shares of the company’s stock worth $13,854,000 after purchasing an additional 140,577 shares during the last quarter. Cambria Investment Management L.P. lifted its holdings in Pediatrix Medical Group by 25.0% during the 3rd quarter. Cambria Investment Management L.P. now owns 38,207 shares of the company’s stock worth $640,000 after buying an additional 7,641 shares during the period. Hancock Whitney Corp grew its position in shares of Pediatrix Medical Group by 30.0% in the 3rd quarter. Hancock Whitney Corp now owns 33,701 shares of the company’s stock valued at $565,000 after buying an additional 7,772 shares during the last quarter. Caxton Associates LLP grew its position in shares of Pediatrix Medical Group by 92.4% in the 3rd quarter. Caxton Associates LLP now owns 31,585 shares of the company’s stock valued at $529,000 after buying an additional 15,167 shares during the last quarter. Finally, Verition Fund Management LLC increased its stake in shares of Pediatrix Medical Group by 4.4% in the third quarter. Verition Fund Management LLC now owns 25,408 shares of the company’s stock valued at $426,000 after buying an additional 1,066 shares during the period. 97.71% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

MD has been the subject of a number of analyst reports. Deutsche Bank Aktiengesellschaft set a $19.00 price objective on Pediatrix Medical Group in a research report on Friday, February 20th. Jefferies Financial Group raised shares of Pediatrix Medical Group to a “strong-buy” rating in a research report on Thursday, March 12th. UBS Group lowered their price target on shares of Pediatrix Medical Group from $23.00 to $22.00 and set a “neutral” rating for the company in a report on Tuesday, February 24th. Truist Financial dropped their price target on shares of Pediatrix Medical Group from $24.00 to $21.00 and set a “hold” rating on the stock in a research report on Thursday, February 19th. Finally, Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Pediatrix Medical Group in a research note on Monday, December 29th. One analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and five have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $19.80.

Pediatrix Medical Group Stock Performance

MD stock opened at $20.88 on Friday. The firm has a market cap of $1.73 billion, a PE ratio of 10.76 and a beta of 0.79. The company has a current ratio of 1.66, a quick ratio of 1.66 and a debt-to-equity ratio of 0.66. The stock has a 50-day moving average price of $20.57 and a 200-day moving average price of $20.21. Pediatrix Medical Group, Inc. has a 1-year low of $11.84 and a 1-year high of $24.99.

Pediatrix Medical Group (NYSE:MD) last announced its earnings results on Thursday, February 19th. The company reported $0.50 EPS for the quarter, missing the consensus estimate of $0.53 by ($0.03). Pediatrix Medical Group had a net margin of 8.64% and a return on equity of 19.59%. The business had revenue of $493.77 million for the quarter, compared to the consensus estimate of $486.23 million. During the same quarter in the previous year, the company earned $0.51 EPS. The firm’s revenue for the quarter was down 1.7% on a year-over-year basis. As a group, equities research analysts expect that Pediatrix Medical Group, Inc. will post 1.38 earnings per share for the current year.

About Pediatrix Medical Group

Pediatrix Medical Group, Inc (NYSE:MD) is a national physician-led medical group specializing in high-acuity newborn, maternal-fetal and pediatric subspecialty care. Headquartered in Sunrise, Florida, the company delivers clinical services through hospital-based physician staffing, advanced practitioner support and telemedicine programs. Its core specialties include neonatology, maternal-fetal medicine, pediatric cardiology, pediatric critical care, pediatric emergency medicine and anesthesiology.

Founded in 1979 and formerly known as MEDNAX, the company rebranded as Pediatrix Medical Group in 2022 to align its corporate identity with its primary clinical offerings.